Cargando…

Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study

GSK3532795 (formerly BMS955176) is a second-generation maturation inhibitor (MI) that progressed through a Phase 2b study for treatment of HIV-1 infection. Resistance development to GSK3532795 was evaluated through in vitro methods and was correlated with information obtained in a Phase 2a proof-of-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dicker, Ira, Zhang, Sharon, Ray, Neelanjana, Beno, Brett R., Regueiro-Ren, Alicia, Joshi, Samit, Cockett, Mark, Krystal, Mark, Lataillade, Max
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797179/ https://www.ncbi.nlm.nih.gov/pubmed/31622432 http://dx.doi.org/10.1371/journal.pone.0224076

Ejemplares similares

The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor–Resistant Clinical Isolates
por: Ray, Neelanjana, et al.
Publicado: (2017)

Antiviral Activity, Safety, and Exposure–Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002)
por: Hwang, Carey, et al.
Publicado: (2017)

Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial
por: Morales-Ramirez, Javier, et al.
Publicado: (2018)

GSK3640254 Is a Novel HIV-1 Maturation Inhibitor with an Optimized Virology Profile
por: Dicker, Ira, et al.
Publicado: (2022)

Correction: Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study
Publicado: (2019)

Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors
por: Lin, Zeyu, et al.
Publicado: (2016)

Effects of the HIV‐1 maturation inhibitor GSK3640254 on QT interval in healthy participants
por: Zhang, Ying, et al.
Publicado: (2023)

Phase I evaluation of pharmacokinetics and tolerability of the HIV‐1 maturation inhibitor GSK3640254 and dolutegravir in healthy adults
por: Pene Dumitrescu, Teodora, et al.
Publicado: (2021)

Lack of pharmacokinetic interaction between the HIV‐1 maturation inhibitor GSK3640254 and combination oral contraceptives in healthy women
por: Pene Dumitrescu, Teodora, et al.
Publicado: (2021)

A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants
por: Pene Dumitrescu, Teodora, et al.
Publicado: (2021)

Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next‐generation HIV‐1 maturation inhibitor
por: Joshi, Samit R., et al.
Publicado: (2020)

Relative Bioavailability and Food Effect of GSK3640254 Tablet and Capsule Formulations in Healthy Participants
por: Johnson, Mark, et al.
Publicado: (2022)

Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir
por: Lataillade, Max, et al.
Publicado: (2018)

Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage
por: Nowicka-Sans, Beata, et al.
Publicado: (2016)

Antiviral Properties of HIV-1 Capsid Inhibitor GSK878
por: Wang, Chunfu, et al.
Publicado: (2023)

Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254( )
por: Spinner, Christoph D, et al.
Publicado: (2022)

Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc
por: Rose, Ronald, et al.
Publicado: (2022)

Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database
por: Gartland, Margaret, et al.
Publicado: (2021)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense(®) Entry assay
por: Gartland, Margaret, et al.
Publicado: (2020)

Intrinsic resistance of HIV-2 and SIV to the maturation inhibitor GSK2838232
por: Smith, Robert A., et al.
Publicado: (2023)

HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 sub-group analysis
por: Brinson, Cynthia, et al.
Publicado: (2014)

540 HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis
por: Brinson, Cynthia, et al.
Publicado: (2014)

Safety profile of HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 analysis
por: Lalezari, Jacob, et al.
Publicado: (2014)

1574 Safety Profile of HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Analysis
por: Lalezari, Jacob, et al.
Publicado: (2014)

Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action
por: Langley, David R, et al.
Publicado: (2015)

The safety, tolerability, and pharmacokinetic profile of GSK2838232, a novel 2nd generation HIV maturation inhibitor, as assessed in healthy subjects
por: Johnson, Mark, et al.
Publicado: (2018)

Prevalence and Clinical Significance of HIV Drug Resistance Mutations by Ultra-Deep Sequencing in Antiretroviral-Naïve Subjects in the CASTLE Study
por: Lataillade, Max, et al.
Publicado: (2010)

GSK-3 inhibitors induce chromosome instability
por: Tighe, Anthony, et al.
Publicado: (2007)

Crystal structure of an HIV assembly and maturation switch
por: Wagner, Jonathan M, et al.
Publicado: (2016)

A phase I, first‐in‐human study investigating the safety, tolerability, and pharmacokinetics of the maturation inhibitor GSK3739937
por: Benn, Paul D., et al.
Publicado: (2023)

Einführung in die vektorielle Geometrie und lineare Algebra für Ingenieure und Naturwissenschaftler
por: Jeger, Max, et al.
Publicado: (1967)

Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1
por: Gartland, Margaret, et al.
Publicado: (2022)

Correction to: Nrf2 activation through the PI3K/GSK-3 axisprotects neuronal cells from Aβ-mediatedoxidative and metabolic damage
por: Sotolongo, Krystal, et al.
Publicado: (2020)

Nrf2 activation through the PI3K/GSK-3 axis protects neuronal cells from Aβ-mediated oxidative and metabolic damage
por: Sotolongo, Krystal, et al.
Publicado: (2020)

Functional inactivation of Plasmodium falciparum glycogen synthase kinase GSK3 modulates erythrocyte invasion and blocks gametocyte maturation
por: Alder, Arne, et al.
Publicado: (2022)

Novel Reporter Alleles of GSK-3α and GSK-3β
por: Barrell, William B., et al.
Publicado: (2012)

Protease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation Process
por: Adamson, Catherine S.
Publicado: (2012)

Plasmablastic Lymphoma Associated with Adjacent Mature Plasma Cell Population Exhibiting Opposite Light Chain Restriction
por: Furlan, Karina, et al.
Publicado: (2020)

GSK3β Regulates Brain Energy Metabolism
por: Martin, Stephen A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g6ob66c0d0lki283lvtebcbleg